BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Del Prete M, Arsenault F, Saighi N, Zhao W, Buteau FA, Celler A, Beauregard JM. Accuracy and reproducibility of simplified QSPECT dosimetry for personalized 177Lu-octreotate PRRT. EJNMMI Phys 2018;5:25. [PMID: 30318563 DOI: 10.1186/s40658-018-0224-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Desy A, Bouvet GF, Frezza A, Després P, Beauregard JM. Impact of dead time on quantitative 177Lu-SPECT (QSPECT) and kidney dosimetry during PRRT. EJNMMI Phys 2020;7:32. [PMID: 32415492 DOI: 10.1186/s40658-020-00303-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Devasia TP, Dewaraja YK, Frey KA, Wong KK, Schipper MJ. A Novel Time-Activity Information-Sharing Approach Using Nonlinear Mixed Models for Patient-Specific Dosimetry with Reduced Imaging Time Points: Application in SPECT/CT After 177Lu-DOTATATE. J Nucl Med 2021;62:1118-25. [PMID: 33443063 DOI: 10.2967/jnumed.120.256255] [Reference Citation Analysis]
3 Taïeb D, Jha A, Treglia G, Pacak K. Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups. Endocr Relat Cancer 2019;26:R627-52. [PMID: 31561209 DOI: 10.1530/ERC-19-0165] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 12.5] [Reference Citation Analysis]
4 Staanum PF, Frellsen AF, Olesen ML, Iversen P, Arveschoug AK. Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates. EJNMMI Phys 2021;8:78. [PMID: 34773508 DOI: 10.1186/s40658-021-00422-2] [Reference Citation Analysis]
5 Monserrat Fuertes T, González García FM, Peinado Montes MÁ, Domínguez Grande ML, Martín Fernández N, Gómez de Iturriaga Piña A, Mínguez Gabiña P. Description of the methodology for dosimetric quantification in treatments with 177Lu-DOTATATE. Rev Esp Med Nucl Imagen Mol (Engl Ed) 2021;40:167-78. [PMID: 33811003 DOI: 10.1016/j.remn.2021.02.006] [Reference Citation Analysis]
6 Kurth J, Heuschkel M, Tonn A, Schildt A, Hakenberg OW, Krause BJ, Schwarzenböck SM. Streamlined Schemes for Dosimetry of 177Lu-Labeled PSMA Targeting Radioligands in Therapy of Prostate Cancer. Cancers (Basel) 2021;13:3884. [PMID: 34359784 DOI: 10.3390/cancers13153884] [Reference Citation Analysis]
7 Ligonnet T, Pistone D, Auditore L, Italiano A, Amato E, Campennì A, Schaefer N, Boughdad S, Baldari S, Gnesin S. Simplified patient-specific renal dosimetry in 177Lu therapy: a proof of concept. Phys Med 2021;92:75-85. [PMID: 34875425 DOI: 10.1016/j.ejmp.2021.11.007] [Reference Citation Analysis]
8 Huot Daneault A, Desaulniers M, Beauregard JM, Beaulieu A, Arsenault F, April G, Turcotte É, Buteau FA. Highly Symptomatic Progressing Cardiac Paraganglioma With Intracardiac Extension Treated With 177Lu-DOTATATE: A Case Report. Front Endocrinol (Lausanne) 2021;12:705271. [PMID: 34367072 DOI: 10.3389/fendo.2021.705271] [Reference Citation Analysis]
9 Frezza A, Desport C, Uribe C, Zhao W, Celler A, Després P, Beauregard JM. Comprehensive SPECT/CT system characterization and calibration for 177Lu quantitative SPECT (QSPECT) with dead-time correction. EJNMMI Phys 2020;7:10. [PMID: 32060777 DOI: 10.1186/s40658-020-0275-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
10 Santoro L, Pitalot L, Trauchessec D, Mora-Ramirez E, Kotzki PO, Bardiès M, Deshayes E. Clinical implementation of PLANET® Dose for dosimetric assessment after [177Lu]Lu-DOTA-TATE: comparison with Dosimetry Toolkit® and OLINDA/EXM® V1.0. EJNMMI Res 2021;11:1. [PMID: 33394212 DOI: 10.1186/s13550-020-00737-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
11 Pandit-Taskar N, Iravani A, Lee D, Jacene H, Pryma D, Hope T, Saboury B, Capala J, Wahl RL. Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice. J Nucl Med 2021;62:60S-72S. [PMID: 34857623 DOI: 10.2967/jnumed.121.262977] [Reference Citation Analysis]
12 Desy A, Bouvet GF, Croteau É, Lafrenière N, Turcotte ÉE, Després P, Beauregard JM. Quantitative SPECT (QSPECT) at high count rates with contemporary SPECT/CT systems. EJNMMI Phys 2021;8:73. [PMID: 34718900 DOI: 10.1186/s40658-021-00421-3] [Reference Citation Analysis]
13 Finocchiaro D, Gear JI, Fioroni F, Flux GD, Murray I, Castellani G, Versari A, Iori M, Grassi E. Uncertainty analysis of tumour absorbed dose calculations in molecular radiotherapy. EJNMMI Phys 2020;7:63. [PMID: 33044651 DOI: 10.1186/s40658-020-00328-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
14 Wong RKS, Metser U, Veit-Haibach P. Neuroendocrine Tumors: Imaging Perspective. PET Clin 2021;16:353-64. [PMID: 34053579 DOI: 10.1016/j.cpet.2021.03.002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Huizing DMV, Peters SMB, Versleijen MWJ, Martens E, Verheij M, Sinaasappel M, Stokkel MPM, de Wit-van der Veen BJ. A head-to-head comparison between two commercial software packages for hybrid dosimetry after peptide receptor radionuclide therapy. EJNMMI Phys 2020;7:36. [PMID: 32488632 DOI: 10.1186/s40658-020-00308-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
16 Rinscheid A, Kletting P, Eiber M, Beer AJ, Glatting G. Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry. EJNMMI Phys 2020;7:41. [PMID: 32556844 DOI: 10.1186/s40658-020-00311-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Zhao W, Esquinas PL, Frezza A, Hou X, Beauregard JM, Celler A. Accuracy of kidney dosimetry performed using simplified time activity curve modelling methods: a 177Lu-DOTATATE patient study. Phys Med Biol 2019;64:175006. [PMID: 31287093 DOI: 10.1088/1361-6560/ab3039] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
18 Del Olmo-García MI, Prado-Wohlwend S, Bello P, Segura A, Merino-Torres JF. Peptide Receptor Radionuclide Therapy with [177Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions. Cancers (Basel) 2022;14:584. [PMID: 35158852 DOI: 10.3390/cancers14030584] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Sjögreen Gleisner K, Chouin N, Gabina PM, Cicone F, Gnesin S, Stokke C, Konijnenberg M, Cremonesi M, Verburg FA, Bernhardt P, Eberlein U, Gear J. EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. Eur J Nucl Med Mol Imaging. [DOI: 10.1007/s00259-022-05727-7] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Malcolm JC, Falzone N, Gains JE, Aldridge MD, Mirando D, Lee BQ, Gaze MN, Vallis KA. Impact of cyclic changes in pharmacokinetics and absorbed dose in pediatric neuroblastoma patients receiving [177Lu]Lu-DOTATATE. EJNMMI Phys 2022;9. [DOI: 10.1186/s40658-022-00436-4] [Reference Citation Analysis]
21 Del Prete M, Buteau FA, Arsenault F, Saighi N, Bouchard LO, Beaulieu A, Beauregard JM. Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial. Eur J Nucl Med Mol Imaging 2019;46:728-42. [PMID: 30506283 DOI: 10.1007/s00259-018-4209-7] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 7.5] [Reference Citation Analysis]
22 Hou X, Zhao W, Beauregard JM, Celler A. Personalized kidney dosimetry in 177Lu-octreotate treatment of neuroendocrine tumours: a comparison of kidney dosimetry estimates based on a whole organ and small volume segmentations. Phys Med Biol 2019;64:175004. [PMID: 31456584 DOI: 10.1088/1361-6560/ab32a1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]